基石藥業(02616.HK):正式發佈四款候選藥物的臨牀前資料
格隆匯 6 月 23日丨基石藥業(02616.HK)宣佈,基石藥業在2020年美國癌症研究協會第二階段虛擬年會上,以電子海報形式首次公佈三款候選藥物的臨牀前資料,分別為一種程式性死亡配體1("PD-L1")單克隆抗體CS1001,一種CDK4/6選擇性小分子抑制劑CS3002和一種蛋白去乙醯化酶6("HDAC6")選擇性小分子抑制劑CS3003。此外,本公司已於近期在中國藥理學報雜誌上發表同行評議文章,全面展示了細胞程式性死亡受體1("PD1")單克隆抗體CS1003的臨牀前特性。
基石藥業首席科學官王辛中博士表示:基石藥業自2015年底成立以來,已將7款自主研發產品順利推進至臨牀階段。近期在美國癌症研究協會第二階段虛擬年會上發表的3篇海報及在中國藥理學報雜誌上發表的同行評議文章均展示了4個核心產品的差異化優勢,包括兩款腫瘤免疫治療的骨架候選藥物PD-L1單克隆抗體CS1001和PD-1單克隆抗體CS1003,一款針對細胞週期調控的靶向藥物CDK4/6小分子抑制劑及一款針對表觀遺傳調控的HDAC6小分子抑制劑,這兩款小分子候選藥物在多種腫瘤動物模型中均表現出同免疫檢查點抑制劑聯合用藥的潛力。我們將在深入理解藥物作用機制的基礎上,制定更有競爭力的臨牀開發策略。同時,我們也以內部研發為驅動,推動公司向管線2.0過渡,為未來持續穩健發展提供動力。
有關重點消息包括:基石藥業在2020年美國癌症研究協會第二階段虛擬年會上發佈了三款臨牀階段候選藥物CS1001、CS3002和CS3003的臨牀前資料,闡述產品的臨牀前特徵、作用機制或/和差異化優勢。
此外,基石藥業在中國藥理學報雜誌上發表的同行評議文章中,全面展示了臨牀階段候選藥物PD-1單克隆抗體CS1003的臨牀前特性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.